In addition, other pharmacologic interventions that were predicted to be effective in this subgroup of medulloblastoma based on gene enrichment analyses are those that inhibit the estrogen-related receptor gamma (ESRRG), the JAK-STAT pathway, and members of the nucleotide biosynthesis pathway, such as dihydrofolate reductase [137]. This evidence concerns the gene ESRRG and medulloblastoma.